<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549701</url>
  </required_header>
  <id_info>
    <org_study_id>090920</org_study_id>
    <nct_id>NCT04549701</nct_id>
  </id_info>
  <brief_title>Inferior Vena CAVA and Lung UltraSound-guided Therapy for the Reduction of Clinical Events in Acute Heart Failure</brief_title>
  <acronym>CAVAL US-HF</acronym>
  <official_title>Inferior Vena CAVA and Lung UltraSound-guided Therapy for the Reduction of Clinical Events in Acute Heart Failure: a Randomized Controlled Clinical Trial (CAVAL US-HF Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Cardiovascular de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lucrecia Mar√≠a Burgos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mirta Diez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fernando Botto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Cardiovascular de Buenos Aires</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      New strategies are needed to reduce decompensations and readmissions due to heart failure, it&#xD;
      is unknown whether the management of patients with hospitalized due acute decompensated heart&#xD;
      failure guided by lung and inferior vena cava ultrasound can improve clinical results during&#xD;
      follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>CAVAL US will be performed on all patients, and patients will be blinded to the assigned group.&#xD;
The treating medical team will be blind to the CAVAL US results of the control group.&#xD;
Independent clinicians adjudicating 90-day events will not participate in patient follow-up, and will be blind to the assigned group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Readmission for heart failure, unplanned visit for worsening HF, or death.</measure>
    <time_frame>90 days</time_frame>
    <description>Readmission for heart failure: unscheduled urgent hospital visit and stay longer than 24 hours, requiring medical interventions.&#xD;
Mortality: death of the patient. Unplanned visit for worsening heart failure: unscheduled visit to the emergency department that led to an increase in oral / intravenous therapy, stay less than 24 hours.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Heart Failure</condition>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>CAVAL US group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to the treating medical team, in addition to standard care. Diuretic titration: There will not be a specific treatment protocol, but clinicians will be encouraged to tailor treatment, particularly with the use of diuretics, according to the number of B-lines and dilation in the IVC. The therapeutic objective will be discharge patients normal CAVAL US, with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory alterations that contraindicate discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to this group will receive standard care, and diuretic titration will be based on standard practice (physical examination, symptoms, and laboratory results). The therapeutic objective will be discharge patients with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory abnormalities that contraindicate discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CAVAL US-guided Therapy</intervention_name>
    <description>Patients randomly assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to treating medical team, in addition to the standard care.</description>
    <arm_group_label>CAVAL US group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard of care will be provided.</description>
    <arm_group_label>CAVAL US group</arm_group_label>
    <arm_group_label>Standard of care group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalization for acute decompensated heart failure, new symptoms or worsening of&#xD;
             previous symptoms&#xD;
&#xD;
          -  Hospital stay of 24 hours or more.&#xD;
&#xD;
          -  NT pro BNP&gt; 300 nl / L within 24 hours of admission&#xD;
&#xD;
          -  Sufficient ultrasound visualization to assess IVC and lungs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not willing to participate&#xD;
&#xD;
          -  Life expectancy of less than 6 months.&#xD;
&#xD;
          -  Uninterpretable pulmonary or inferior vena cava ultrasound&#xD;
&#xD;
          -  Transfer to another hospital before discharge from hospital&#xD;
&#xD;
          -  Chronic kidney disease&#xD;
&#xD;
          -  Requirement for invasive or non-invasive ventilatory assistance&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Low cardiac output syndrome&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Death during index hospitalization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Cardiovascular de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <state>Buenos Aires City</state>
        <zip>1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <contact>
      <last_name>Lucrecia Burgos, MD</last_name>
      <email>Lburgos@icba.com.ar</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Cardiovascular de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Lucrecia Maria Burgos</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

